Real-World Experience of CPX-351 As First-Line Treatment in 188 Patients with Acute Myeloid LeukemiaChristina Rautenberg, M. Middeke, Oliver Kriege et al.|Blood|2021Cited by 3
Polycomb Protein RING1A Limits Differentiation in Myelodysplastic SyndromesAnna Palau, Marcus Buschbeck, Anabel Zwick et al.|Leukemia Research|2017Cited by 0
DNMT3A mutations in exon 23 are associated with improved survival in AML patients treated with Azacytidine plus standard chemotherapyPetra Tschanter, Carsten Müller‐Tidow, Utz Krug et al.|Kölner Universitäts PublikationsServer (Universität zu Köln)|2015Cited by 0